OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Abdulkadir on the Challenges of Targeting MYC in Prostate Cancer

November 10th 2020

Sarki A. Abdulkadir, MD, PhD, discusses the challenges of targeting MYC in prostate cancer.

Dr. Ahn on the Role of Checkpoint Inhibitors in NTRK Fusion+ MSI-H CRC

November 10th 2020

Daniel H. Ahn, DO, discusses the role of checkpoint inhibitor therapy in patients with microsatellite instability–high colorectal cancer who harbor an NTRK fusion.

Dr. Benson on the Complexity of Up-front Treatment in HCC

November 10th 2020

Al B. Benson, MD, discusses the complexity of up-front treatment in hepatocellular carcinoma.

Dr. Lunning on Initial Treatment Considerations in CLL

November 10th 2020

Matthew A. Lunning, DO, discusses initial treatment considerations in chronic lymphocytic leukemia.

Dr. Beltran on the Significance of Genomic Sequencing in Prostate Cancer

November 9th 2020

Himisha Beltran, MD, discusses the significance of genomic sequencing in prostate cancer.

Dr. Skarbnik on the Approval of Brexucabtagene Autoleucel in MCL

November 9th 2020

Alan P. Z. Skarbnik, MD, discusses the approval of brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma.

Dr. Krop on the Role of Neratinib as Extended Adjuvant Therapy in HR+/HER2+ Breast Cancer

November 9th 2020

Ian E. Krop, MD, PhD, discusses the role of neratinib as extended adjuvant therapy in high-risk, hormone receptor–positive, HER2-positive breast cancer.

Dr. Rohs on the Importance of Genetic Testing in NSCLC

November 7th 2020

Nicholas C. Rohs, MD, discusses the importance of genetic testing in non–small cell lung cancer.

Dr. Rizk on the Evolution of Surgery in Lung Cancer

November 7th 2020

Nabil P. Rizk, MD, MS, MPH, discusses the evolving role of surgery in lung cancer.

Dr. McGregor the Potential Utility of Cabozantinib/Nivolumab in Advanced RCC

November 7th 2020

Bradley McGregor, MD, discusses the potential utility of the combination of cabozantinib and nivolumab in advanced renal cell carcinoma (RCC).

Dr. Vaishampayan on the Expanding Role of TKI/Immunotherapy Combinations in mRCC

November 6th 2020

Ulka N. Vaishampayan, MBBS, FAB, discusses the expanding role of TKI/immunotherapy combinations in metastatic renal cell carcinoma.

Dr. Rini on Choosing Between IO/IO or IO/TKI Combinations in mRCC

November 6th 2020

Brian I. Rini, MD, discusses choosing between combinations of dual immunotherapy and immunotherapy/VEGF TKIs in metastatic renal cell carcinoma.

Dr. Markman on the Benefit of PARP Inhibitors in Ovarian Cancer

November 6th 2020

Maurie Markman, MD, discusses the utility of PARP inhibitors in ovarian cancer.

Dr. Yu on the Role of Radiation in Prostate Cancer

November 6th 2020

James B. Yu, MD, MHS, discusses the utility of radiation in men with prostate cancer.

Dr. Braunschweig on Mitigating the Toxicities of CAR T-Cell Therapy in Lymphoma

November 5th 2020

Ira Braunschweig, MD, discusses mitigating the toxicities that are associated with CAR T-cell therapy in lymphoma.

Dr. Sun on the Use of Ramucirumab/Paclitaxel in Metastatic Gastric Cancer

November 5th 2020

Weijing Sun, MD, FACP, discusses the use of ramucirumab plus paclitaxel in metastatic gastric cancer.

Dr. Cavnar on the Management of Liver Metastases in CRC

November 5th 2020

Michael J. Cavnar, MD, discusses the management of patients with liver metastases in colorectal cancer.

Dr. Abraham on Surgical Improvements in TGCT

November 5th 2020

John A. Abraham, MD, FACS, discusses surgical improvements in tenosynovial giant cell tumor.

Dr. Mahal on the Emerging Role of Epigenomics in Prostate Cancer

November 5th 2020

Brandon Mahal, MD, discusses the emerging role of epigenomics in prostate cancer.

Dr. Popat on Unmet Needs in Triple-Class Refractory Multiple Myeloma

November 5th 2020

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses unmet needs in triple-class refractory multiple myeloma.